ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
CNY 9.2
(5.75%)
CNY 9.2
(5.75%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 25.19 Million CNY | 121.25% |
| 2022 | -118.57 Million CNY | -29.68% |
| 2021 | -91.43 Million CNY | 65.15% |
| 2020 | -262.36 Million CNY | -5053.33% |
| 2019 | 5.29 Million CNY | -26.85% |
| 2018 | 7.24 Million CNY | -66.59% |
| 2017 | 21.67 Million CNY | -28.11% |
| 2016 | 30.14 Million CNY | 31.65% |
| 2015 | 22.9 Million CNY | -44.14% |
| 2014 | 40.99 Million CNY | 51.21% |
| 2013 | 27.11 Million CNY | 5.08% |
| 2012 | 25.8 Million CNY | -27.0% |
| 2011 | 35.34 Million CNY | -26.34% |
| 2010 | 47.98 Million CNY | 66.03% |
| 2009 | 28.9 Million CNY | 121.71% |
| 2008 | 13.03 Million CNY | 0.0% |
| 2007 | 13.03 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 10.65 Million CNY | -30.01% |
| 2024 Q1 | 18.28 Million CNY | -52.98% |
| 2024 Q2 | 15.21 Million CNY | -16.77% |
| 2023 Q4 | 38.88 Million CNY | 272.82% |
| 2023 FY | 25.19 Million CNY | 121.25% |
| 2023 Q2 | -21.96 Million CNY | -918.42% |
| 2023 Q3 | 10.43 Million CNY | 147.49% |
| 2023 Q1 | -2.15 Million CNY | 97.69% |
| 2022 Q1 | -1.54 Million CNY | 98.21% |
| 2022 Q4 | -93.2 Million CNY | -3560.65% |
| 2022 FY | -118.57 Million CNY | -29.68% |
| 2022 Q3 | -2.54 Million CNY | 88.04% |
| 2022 Q2 | -21.28 Million CNY | -1281.61% |
| 2021 FY | -91.43 Million CNY | 65.15% |
| 2021 Q1 | 1.01 Million CNY | 100.73% |
| 2021 Q2 | -5.13 Million CNY | -604.37% |
| 2021 Q3 | -1.26 Million CNY | 75.3% |
| 2021 Q4 | -86.05 Million CNY | -6681.55% |
| 2020 Q4 | -138.63 Million CNY | -185.87% |
| 2020 FY | -262.36 Million CNY | -5053.33% |
| 2020 Q1 | -43.65 Million CNY | -13.95% |
| 2020 Q2 | -31.57 Million CNY | 27.65% |
| 2020 Q3 | -48.49 Million CNY | -53.58% |
| 2019 FY | 5.29 Million CNY | -26.85% |
| 2019 Q4 | -38.3 Million CNY | -2703.2% |
| 2019 Q3 | 1.47 Million CNY | -93.39% |
| 2019 Q2 | 22.26 Million CNY | 12.1% |
| 2019 Q1 | 19.86 Million CNY | 236.0% |
| 2018 Q4 | -14.6 Million CNY | -428.94% |
| 2018 Q3 | 4.44 Million CNY | -55.99% |
| 2018 FY | 7.24 Million CNY | -66.59% |
| 2018 Q1 | 7.31 Million CNY | 416.85% |
| 2018 Q2 | 10.08 Million CNY | 37.89% |
| 2017 Q3 | 2.67 Million CNY | -82.08% |
| 2017 Q4 | -2.3 Million CNY | -186.39% |
| 2017 FY | 21.67 Million CNY | -28.11% |
| 2017 Q1 | 6.39 Million CNY | 495.41% |
| 2017 Q2 | 14.91 Million CNY | 133.3% |
| 2016 FY | 30.14 Million CNY | 31.65% |
| 2016 Q4 | 1.07 Million CNY | -88.12% |
| 2016 Q3 | 9.04 Million CNY | -32.55% |
| 2016 Q2 | 13.4 Million CNY | 102.24% |
| 2016 Q1 | 6.62 Million CNY | 189.75% |
| 2015 Q4 | -7.38 Million CNY | -165.55% |
| 2015 FY | 22.9 Million CNY | -44.14% |
| 2015 Q1 | 7.28 Million CNY | -24.33% |
| 2015 Q2 | 11.73 Million CNY | 61.0% |
| 2015 Q3 | 11.26 Million CNY | -3.96% |
| 2014 Q3 | 11.57 Million CNY | -10.78% |
| 2014 FY | 40.99 Million CNY | 51.21% |
| 2014 Q1 | 6.82 Million CNY | -0.2% |
| 2014 Q2 | 12.97 Million CNY | 90.03% |
| 2014 Q4 | 9.62 Million CNY | -16.79% |
| 2013 Q4 | 6.83 Million CNY | 1.42% |
| 2013 FY | 27.11 Million CNY | 5.08% |
| 2013 Q1 | 5.21 Million CNY | -40.29% |
| 2013 Q2 | 8.31 Million CNY | 59.66% |
| 2013 Q3 | 6.74 Million CNY | -18.93% |
| 2012 Q4 | 8.72 Million CNY | 98.54% |
| 2012 FY | 25.8 Million CNY | -27.0% |
| 2012 Q2 | 7.17 Million CNY | 30.44% |
| 2012 Q3 | 4.39 Million CNY | -38.75% |
| 2012 Q1 | 5.5 Million CNY | 74.54% |
| 2011 Q2 | 13.64 Million CNY | 36.16% |
| 2011 Q1 | 10.02 Million CNY | -41.72% |
| 2011 FY | 35.34 Million CNY | -26.34% |
| 2011 Q4 | 3.15 Million CNY | -62.99% |
| 2011 Q3 | 8.51 Million CNY | -37.61% |
| 2010 Q4 | 17.2 Million CNY | 258.49% |
| 2010 Q3 | 4.79 Million CNY | 0.0% |
| 2010 FY | 47.98 Million CNY | 66.03% |
| 2009 FY | 28.9 Million CNY | 121.71% |
| 2008 FY | 13.03 Million CNY | 0.0% |
| 2007 FY | 13.03 Million CNY | 0.0% |